Change of adviser and directorate update

RNS Number : 2815I

Venture Life Group PLC

23 November 2018

 

23 November 2018

Venture Life Group plc

("Venture Life" or "the Company")

Change of adviser and directorate update

Change of adviser

Venture Life Group plc (AIM: VLG), the international consumer self-care company, is pleased to announce the appointment, with immediate effect, of Cenkos Securities plc as its Nominated Adviser and sole broker.

Disclosures required by Schedule 2(g) of the AIM Rules for Companies

At the time of Venture Life's admission to trading on AIM on 24 March 2014, it was disclosed in the Company's admission document that Jerry Randall had been a director within the five years prior to date of publication of the admission document of Sinclair Pharma plc ("Sinclair Pharma") and Silence Therapeutics plc ("Silence Therapeutics") and various group companies of Sinclair Pharma and Silence Therapeutics. These group companies are Sinclair Pharma UK Limited, Sinclair Pharmaceuticals Limited, Silence Therapeutics (London) Limited and Innopeg Limited. Jerry Randall is also a director of Venture Life Limited and Lubatti Limited (both of which are Venture Life group companies) and was, until 8^th March 2016, a director of Softto Lubatti Limited, a Venture Life group company.  Further, Sharon Collins is a director of Venture Life Limited and Lubatti Limited and a former director of Tracey Malone Originals Limited. Lastly, Gianluca Braguti is a director of Biokosmes SRL, a Venture Life group company.

Contacts

Venture Life Group PLC	[phone]
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)	[phone]
Mark Connelly / Cameron MacRitchie (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Walbrook PR	+ 44 (0) 20 7933 8780
Anna Dunphy /Paul McManus	[e-mail]
[phone] / [phone]

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

END

 

 

APPPGGQCGUPRPUP